Alnylam

Hympavzi

Pharma

FDA signs off on pediatric use of Pfizer's hemophilia treatment

The FDA has expanded the label for Pfizer’s subcutaneous Hympavzi, now including patients age 6 and older who have hemophilia A or B.

Kevin Dunleavy Jun 8, 2026 10:32am

Amvuttra

Alnylam rebuked by FDA over efficacy claims on Amvuttra website

May 7, 2026 5:18am

Space shuttle takes off on background of blue sky

As questions swirl, Alnylam eyes ATTR market leadership by 2030

Mar 26, 2026 2:08pm

Collage poster study of businessmen picture chart arrow goes up

Orphan drug sales to surge past $400B in 2032: report

Mar 12, 2026 8:20am

Lifeline

Fierce Biotech

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm

red tape delay stop error tie down stall

Alnylam hits profitability in Q4 despite Amvuttra revenue miss

Feb 12, 2026 11:05am